Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Chlorzoxazone
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Sponsor : Senores Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Chlorzoxazone Tablets USP, 250 mg, a therapeutic equivalent version of Paraflex (Chlorzoxazone) is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal condition...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 05, 2021
Lead Product(s) : Chlorzoxazone
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Sponsor : Senores Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Chlorzoxazone
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Mayne Pharma Launches Chlorzoxazone Tablet in the United States
Details : FDA has granted approval of its Abbreviated New Drug Application (ANDA) for chlorzoxazone tablet, 375 mg, 500 mg and 750 mg, in the United States.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 28, 2020
Lead Product(s) : Chlorzoxazone
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?